PhRMA: Need For Long-Term Japan Pharma Policies
This article was originally published in PharmAsia News
The U.S. industry association PhRMA continues to see substantial progress with regulatory and healthcare reforms in Japan but stresses the remaining need for long-term policies that encourage innovation, foreign investment and the broader use of modern vaccines.
You may also be interested in...
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.